From: Pathological transition as the arising mechanism for drug resistance in lung cancer
Patient ID | Gender | Age | Smoking status | Therapy | 1st biopsya | 2nd biopsyb | References | ||
---|---|---|---|---|---|---|---|---|---|
Pathological status | Mutation status | Pathological status | Mutation status | ||||||
1 | M | 54 | NA | TKI | ADC | EGFR 19 del | SCLC | EGFR 19 del | [32] |
2 | F | 56 | NA | TKI | ADC | EGFR 19 del | SCLC | EGFR 19 del | [32] |
3 | F | 61 | NA | TKI | ADC | EGFR 19 del | SCLC | EGFR 19 del | [32] |
4 | F | 72 | N | Gef | ADC | EGFR 19 del | SCLC | EGFR 19 del | [91] |
5 | F | 46 | N | Erl | ADC | EGFR 19 del | SCLC | EGFR 19 del | [92] |
6 | F | 52 | N | Erl | ADC | EGFR 19 del | SCLC | EGFR 19 del | [93] |
7 | M | 80 | N | Ico | ADC | EGFR 19 del | SCLC | EGFR 19 del | [94] |
8 | F | 63 | N | Erl | ADC | EGFR 19 del | SCLC | EGFR 19 del | [95] |
9 | M | 46 | Y | Gef | ADC | EGFR 19 del | SCLC | EGFR 19 del | [96] |
10 | M | 49 | Y | Erl | ADC | EGFR 19 del and FGFR3 exon 17 deletion | SCLC | EGFR 19 del and FGFR3 exon 17 deletion | [97] |
11 | F | 60 | N | Gef | ADC | EGFR 19 del | SCLC | EGFR 19 del | [98] |
12 | M | 65 | N | Afa | ADC | EGFR 19 del | SCLC | EGFR 19 del | [99] |
13 | F | 37 | N | Gef | ADC | EGFR 19 del | SCLC | EGFR 19 del + T790M | [100] |
14 | F | 42 | N | Erl | ADC | EGFR 19 del | SCLC | EGFR 19 del + T790M | [101] |
15 | F | 49 | N | Gef | ADC | EGFR 19 del | SCLC | NA | [102] |
16 | M | 41 | Y | Gef | ADC | EGFR 19 del | SCLC + SCC | NA | [61] |
17 | M | 74 | Y | Gef | ADC | EGFR 19 del | SCLC | WT | [103] |
18 | F | 48 | NA | TKI | ADC | EGFR L858R | SCLC | EGFR L858R | [32] |
19 | F | 67 | NA | TKI | ADC | EGFR L858R | SCLC | EGFR L858R | [32] |
20 | F | 72 | N | Gef | ADC | EGFR L858R | SCLC | EGFR L858R | [104] |
21 | M | 46 | N | Gef | ADC | EGFR L858R | SCLC | EGFR L858R | [105] |
22 | M | 49 | Y | Gef | ADC | EGFR L858R | SCLC | EGFR L858R | [106] |
23 | F | 65 | N | Gef | ADC | EGFR L858R | SCLC | EGFR L858R | [107] |
24 | M | 73 | NA | Gef | ADC | EGFR L858R | SCLC | EGFR L858R | [108] |
25 | F | 40 | NA | TKI | ADC | EGFR L858R | SCLC | EGFR L858R and PIK3CA | [32] |
26 | M | 38 | N | Erl | ADC | EGFR L858R | SCLC | NA | [109] |
27 | M | 72 | Y | Crizo | ADC | ALK | SCLC | ALK | [33] |
28 | M | 67 | N | Alec | ADC | ALK | SCLC | ALK | [34] |
29 | F | 72 | N | Gef | ADC | WT | SCLC | NA | [35] |
30 | M | 61 | N | TKI | ADC | NA | SCLC | EGFR 19 del | [110] |
31 | F | 46 | N | Gef | ADC | NA | SCLC | EGFR 19 del | [111] |
32 | F | 45 | N | Erl- Gef | ADC | NA | SCLC | EGFR 19 del | [31] |
33 | F | 73 | N | Gef | ADC | NA | SCLC | EGFR L858R | [104] |